Open Nav

SaNOtize Research and Development Corp

fundraising, preparation for Series A

  • Date:Thursday, October 18
  • Time:9:45 AM - 10:00 AM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Nitric Oxide (NO) is an antimicrobial, anti-inflammatory, vasodilator and wound healing promotor. SaNOtize has developed and patented (issued) a Nitric Oxide Releasing Solution - platform technology, to treat and prevent microbial infections. SaNOtize found the way to deliver nitric oxide, without the gas cylinders, in a way that is safe to the patient but lethal to all microbes, including drug resistant. 

Target indications include treatment for strep throat, onychomycosis, sinusitis, acne and cold and flu prevention. The company has successfully completed a phase I clinical trial for foot fungal infection, with a No Objection Letter from Health Canada, showing safety and efficacy.  The two founders, Dr. Regev and Dr. Miller, have a combine of 40 years of clinical research experience, with over 25 years in nitric oxide field. Both have successfully brought nitric oxide based drugs and devices to clinical development.
  • Company
  • Company HQ City:Vancouver
  • Company HQ Country:Canada
  • Company HQ State:British Columbia
  • CEO/Top Company Official:Dr Gilly Regev
  • Year Founded:2017 (spun out of a parent company)
  • Main Therapeutic Focus:Infectious Diseases
  • Lead Product in Development :athlete's foot/onychomycosis
  • Development Phase of Primary Product:Phase I
  • Additional Information/Comments:We would appreciate the opportunity to come and present in October 2018 as we believe we will be in a position to raise Series A.
  • Previous and Current Investors:angels
  • Size of Last Investment Round:raising now $1.3M
  • Total Amount Raised to Date, In All Rounds:$3M to develop technology
Gilly Regev
SaNOtize Research and Development Corp